Passive antibody therapy for infectious diseases

被引:378
作者
Casadevall, A [1 ]
Dadachova, E
Pirofski, L
机构
[1] Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Microbiol, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Nucl Med, Bronx, NY 10461 USA
关键词
D O I
10.1038/nrmicro974
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Antibody-based therapies are currently undergoing a renaissance. After being developed and then largely abandoned in the twentieth century, many antibody preparations are now in clinical use. However, most of the reagents that are available target non-infectious diseases. Interest in using antibodies to treat infectious diseases is now being fuelled by the wide dissemination of drug-resistant microorganisms, the emergence of new microorganisms, the relative inefficacy of antimicrobial drugs in immunocompromised hosts and the fact that antibody-based therapies are the only means to provide immediate immunity against biological weapons. Given the need for new antimicrobial therapies and many recent technological advances in the field of immunoglobulin research, there is considerable optimism regarding renewed applications of antibody-based therapy for the prevention and treatment of infectious diseases.
引用
收藏
页码:695 / 703
页数:9
相关论文
共 67 条
  • [51] The heparin-binding haemagglutinin of M-tuberculosis is required for extrapulmonary dissemination
    Pethe, K
    Alonso, S
    Biet, F
    Delogu, G
    Brennan, MJ
    Locht, C
    Menozzi, FD
    [J]. NATURE, 2001, 412 (6843) : 190 - 194
  • [52] Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens
    Pirofski, LA
    [J]. TRENDS IN MICROBIOLOGY, 2001, 9 (09) : 445 - 451
  • [53] POLONELLI L, 1994, J IMMUNOL, V152, P3175
  • [54] PERSPECTIVE - HYPOTHESIS - SERUM IGG ANTIBODY IS SUFFICIENT TO CONFER PROTECTION AGAINST INFECTIOUS-DISEASES BY INACTIVATING THE INOCULUM
    ROBBINS, JB
    SCHNEERSON, R
    SZU, SC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (06) : 1387 - 1398
  • [55] Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth
    Rodrigues, ML
    Travassos, LR
    Miranda, KR
    Franzen, AJ
    Rozental, S
    de Souza, W
    Alviano, CS
    Barreto-Bergter, E
    [J]. INFECTION AND IMMUNITY, 2000, 68 (12) : 7049 - 7060
  • [56] Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor
    Samuelsson, A
    Towers, TL
    Ravetch, JV
    [J]. SCIENCE, 2001, 291 (5503) : 484 - 486
  • [57] More is not necessarily better: Prozone-like effects in passive immunization with IgG
    Taborda, CP
    Rivera, J
    Zaragoza, O
    Casadevall, A
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (07) : 3621 - 3630
  • [58] Immunoglobulin m efficacy against Cryptococcus neoformans:: Mechanism, dose dependence, and prozone-like effects in passive protection experiments
    Taborda, CP
    Casadevall, A
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (03) : 2100 - 2107
  • [59] EQUINE ANTITOXIN USE AND OTHER FACTORS THAT PREDICT OUTCOME IN TYPE-A FOODBORNE BOTULISM
    TACKET, CO
    SHANDERA, WX
    MANN, JM
    HARGRETT, NT
    BLAKE, PA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1984, 76 (05) : 794 - 798
  • [60] Taylor RP, 1997, J IMMUNOL, V159, P4035